



# Maintaining Participant Contact: June-December 2015 and Results dissemination

Krina Reddy (M.Med Sci) - Study Coordinator
Wits Reproductive Health and HIV Institute (Wits RHI)

MTN Annual Meeting 2015
Bethesda North Marriott Hotel & Conference Center, Maryland, USA
15 March 2015

# OUTLINE

- Introduction
- Plans for maintaining participant contact
- Plans for results dissemination
- Summary
- Acknowledgments



### INTRODUCTION

- Maintaining contact with participants after termination from the study is critical:
  - Optimize ASPIRE result dissemination
  - Optimize screening and enrolment into MTN 025 (HOPE)
- Participants enrolled: 213
- Participants in follow up: 198
- Why the discrepancy?

Transferred out	4 [To Cape Town (2) & Zimbabwe sites (2)]
Transferred in	6 [From Zimbabwe (2), Cape Town (1) & Durban (3) sites ]
Termination	17

Aim is to maintain regular contact with all 198 participants



### MAINTAINING CONTACT: CURRENT

- Cohort allocation system
- Community Health Workers (CHWS)
  - Maintain regular contact phone calls, SMS, IM (WhatsApp)
    - Participant/staff rapport
    - Reminders for study visits, special events and general check in
    - Update locator information
  - System has been successful
    - 96% retention excluding early terminations
    - 91% retention overall
- Monitored by Community Liaison Officer (CLO), Study Coordinator (SC)
   & IoR
- IoR, SC, Clinians & CLO also contact participants as needed



### PLANS FOR MAINTAINING CONTACT

#### During study follow up:

- In daily waiting room discussions,
  - Timelines to result dissemination
  - Possibility of HOPE study
  - Importance of maintaining site/participant contact is stressed
- At Product Use End Visit (PUEV) and Study Exit Visit (SEV)
  - Locator information updated
  - Reminder to contact site as needed
  - Future contact log completed (SEV)
  - Contact card (SEV)




### PLANS FOR MAINTAINING CONTACT

#### After SEV:

- CHW will continue with regular contact with participants per allocation system for general check-in & locator update as needed.
- Holiday and Birthday listing to wish participants
  - Use of bulk SMS system, IM (WhatsApp), telephone call
- Site events (e.g. Movie Day, End of Study Party)





## PLANS FOR MAINTAINING CONTACT

#### After SEV:

- Protocol currently being drafted to offer
  - Monthly HIV testing and counseling, pregnancy testing as well as contraception counseling and provision as needed.
- HIV tests & contraception → Gauteng Department of Health (DOH) - free
- Pregnancy test → Currently checking with DOH
- Will only be implemented following IRB approval



### PLANS FOR RESULT DISSEMINATION

- Participants will be provided with feedback with regards to availability of results – Bulk SMS or at site events
- Result Dissemination: Study exit worksheet reponses will be used

#### **Review Study Exit Worksheets**

#### **Create listing**

- Plan for providing participant with final study results
- Method by which participant wishes to be contacted when study results are available

#### **Analyze listing**

Planned and schedule result dissemination
Use communication material supplied by MTN

### PLANS FOR RESULT DISSEMINATION

- Options for result dissemination to participants
  - Group discussions
  - Individual discussions
  - Email/SMS/Instant Messaging/Telephone call
- Options for result dissemination to CAB & Stakeholders (as per the ASPIRE communications plan)
  - Meetings
  - Email
  - Letters



### **SUMMARY**

- Regular contact with participants must be maintained
- Site will continue with cohort allocation approach



- Regular telephonic check-in and update of locator information
- Face to face activities at site (e.g Movie Day)
- Possibly provision of monthly VCT, Pregnancy testing and contraception
- Concerted effort will be made to maintain contact with all 198 participants

# **ACKNOWLEDGMENTS**



Wits RHI Staff, Participants & Partners, Community Advisory Board (CAB), ASPIRE study sites







The Microbicide Trials Network is funded by the National Institute of Allergy and Infectious (UM1AI068633, UM1AI068615, Diseases UM1AI106707), with co-funding from the *Eunice* Kennedy Shriver National Institute of Child Health and Human Development and National Institute of Mental Health, components of the U.S. National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.